NZ598722A - Methods for treating psoriasis - Google Patents

Methods for treating psoriasis

Info

Publication number
NZ598722A
NZ598722A NZ598722A NZ59872210A NZ598722A NZ 598722 A NZ598722 A NZ 598722A NZ 598722 A NZ598722 A NZ 598722A NZ 59872210 A NZ59872210 A NZ 59872210A NZ 598722 A NZ598722 A NZ 598722A
Authority
NZ
New Zealand
Prior art keywords
treating psoriasis
methods
antigen
antibody
subject
Prior art date
Application number
NZ598722A
Other languages
English (en)
Inventor
Joaquin Mario Valdes
Elliot K Chartash
William T Barchuk
Susan K Paulson
Kenneth B Gordon
Walid M Awni
Yanjun Bao
William G Glass
Yihua Gu
Tom C Harris
Martin Kaul
Parvez M Mulani
Peter Noertersheuser
Martin M Okun
Original Assignee
Abbott Gmbh & Co Kg
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg, Abbvie Inc filed Critical Abbott Gmbh & Co Kg
Publication of NZ598722A publication Critical patent/NZ598722A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ598722A 2009-09-14 2010-09-14 Methods for treating psoriasis NZ598722A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US24596709P 2009-09-25 2009-09-25
US29762310P 2010-01-22 2010-01-22
US36029910P 2010-06-30 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
NZ598722A true NZ598722A (en) 2014-05-30

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598722A NZ598722A (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Country Status (15)

Country Link
US (2) US8557239B2 (enExample)
EP (1) EP2477654A4 (enExample)
JP (1) JP2013504598A (enExample)
KR (2) KR20120112384A (enExample)
CN (1) CN102630168A (enExample)
AU (1) AU2010291927A1 (enExample)
CA (1) CA2773556A1 (enExample)
IL (1) IL218633A0 (enExample)
IN (1) IN2012DN01965A (enExample)
MX (1) MX2012003138A (enExample)
NZ (1) NZ598722A (enExample)
RU (1) RU2012114854A (enExample)
SG (1) SG179135A1 (enExample)
TW (1) TW201127400A (enExample)
WO (1) WO2011032148A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20120189637A1 (en) * 2010-10-06 2012-07-26 Valdes Joaquin Mario Methods for treating psoriasis
SG10201505454SA (en) * 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2022137733A1 (ja) * 2020-12-24 2022-06-30 国立大学法人神戸大学 紫外線照射を用いたウイルス不活化方法
EP4305062A1 (en) * 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
BR112023018353A2 (pt) * 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
EP4703379A1 (en) * 2023-04-26 2026-03-04 Innovent Biologics (Suzhou) Co., Ltd. Method for treating psoriasis with recombinant interleukin 23p19 antibody

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
WO1998016248A1 (en) 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
EP0936923B1 (en) 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
KR100764256B1 (ko) 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
US20020161199A1 (en) 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
DK1137766T3 (da) 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
BR0009323A (pt) * 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
CA2550505A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1713502A1 (de) 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US20120189637A1 (en) 2010-10-06 2012-07-26 Valdes Joaquin Mario Methods for treating psoriasis
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Also Published As

Publication number Publication date
MX2012003138A (es) 2012-07-04
RU2012114854A (ru) 2013-10-27
US20110206680A1 (en) 2011-08-25
CN102630168A (zh) 2012-08-08
US20140079714A1 (en) 2014-03-20
EP2477654A1 (en) 2012-07-25
TW201127400A (en) 2011-08-16
CA2773556A1 (en) 2011-03-17
AU2010291927A1 (en) 2012-04-12
WO2011032148A1 (en) 2011-03-17
EP2477654A4 (en) 2013-01-23
US8557239B2 (en) 2013-10-15
KR20120112384A (ko) 2012-10-11
IL218633A0 (en) 2012-05-31
KR20140048229A (ko) 2014-04-23
SG179135A1 (en) 2012-05-30
JP2013504598A (ja) 2013-02-07
IN2012DN01965A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
NZ587765A (en) Methods for treating psoriasis
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
SG179135A1 (en) Methods for treating psoriasis
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY188911A (en) Methods of treating bladder cancer
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
IL201479A (en) Use of tapentadol for the preparation of pain medication
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
PH12013500140A1 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
IN2012DN03172A (enExample)
WO2012048134A3 (en) Methods for treating psoriasis
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
UA33293U (ru) Способ лечения хронического эндометрита
UA66406U (ru) Способ лечения остеопенического синдрома у беременных с перинатальным инфицированием
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
UA65561U (ru) Способ профилактики задержания помета у коров

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBOTT GMBH, DE

Effective date: 20140410

Owner name: ABBVIE INC., US

Effective date: 20140410

ASS Change of ownership

Owner name: ABBVIE DEUTSCHLAND GMBH, DE

Effective date: 20140605

Owner name: ABBVIE INC., US

Effective date: 20140605

PSEA Patent sealed
ASS Change of ownership

Owner name: ABBVIE DEUTSCHLAND GMBH, DE

Effective date: 20140929

Owner name: ABBVIE INC., US

Effective date: 20140929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2015 BY SPRUSON + FERGUSON

Effective date: 20141222

LAPS Patent lapsed